Intuitive Surgical (ISRG) has gained nearly 12% in a month, outperforming the market ahead of Q3 earnings. The company benefits from strong da Vinci 5 adoption, growing Ion procedures, and expanding international markets. However, slower U.S. procedure growth, GLP-1 drug competition affecting bariatric procedures, and China headwinds pose risks. ISRG trades at a premium 36.04X forward P/E but remains attractive with a Zacks Rank #2 (Buy) rating.

Johnson & Johnson's shares fell 5.8% after Q3 2026 results showed earnings beat but sales missed expectations. MedTech segment underperformed with only 2.5% growth due to Abiomed declines and international market challenges, while Innovative Medicine remained strong. Despite headwinds, J&J raised full-year guidance and targets over $100 billion in 2026 revenue with accelerated growth expected in 2027.

Medtronic stock closed up 1.17% at $93.01, outperforming the broader market decline. The company is expected to report quarterly EPS of $1.34 (down 1.47% YoY) and revenue of $9.47 billion (up 5.66% YoY). With a Zacks Rank of #3 (Hold) and a Forward P/E of 15.38 (below industry average of 19.61), MDT trades at a valuation discount despite modest earnings headwinds.

Abbott Laboratories and Intuitive Surgical represent different healthcare investment strategies. Abbott offers diversified operations across diagnostics, nutrition, and medical devices with a conservative 18x forward P/E ratio, $7.4B free cash flow, and 2.49% dividend yield. Intuitive Surgical commands a premium 39x P/E multiple but delivers 21% revenue growth, zero debt, and dominance in robotic-assisted surgery. Both companies project ~13% sales growth for 2026, but Abbott's lower valuation and new Cologuard cancer screening acquisition make it the better buy for long-term value investors.

The article recommends four healthcare stocks across two key niches: GLP-1 weight-loss drugs (Eli Lilly and Novo Nordisk) and surgical robotics (Intuitive Surgical and Medtronic). Eli Lilly leads in GLP-1 but faces patent expiration risks, while Novo Nordisk is a turnaround story with attractive valuation. Intuitive Surgical dominates surgical robotics with strong recurring revenue, while Medtronic offers a diversified play with dividend appeal as it launches its Hugo surgical robot.

ResearchAndMarkets.com released a comprehensive market report on China's airway management sector, covering historical data from 2018 and forecasts through 2033. The report segments the market into Airway Management Tubes and Intubation Accessories, providing revenue, volume, and pricing analysis. It includes 2025 company share data and profiles of key competitors to support strategic planning and investment decisions in this growing medical device market.

As inflation concerns persist amid Middle East geopolitical tensions and rising energy prices, healthcare stocks are positioned as defensive investments. Medtronic, a turnaround story with strong dividend history and accelerating growth, appeals to value investors. Eli Lilly, a GLP-1 drug leader expanding its pipeline, offers growth potential. Both companies benefit from healthcare's historical resilience to inflation.

The global bioelectronic medicine market is projected to grow from USD 8.9 billion in 2025 to USD 21.6 billion by 2034, driven by increasing adoption of neuromodulation technologies, advances in implantable devices, AI integration, and expanding applications beyond neurological disorders. North America leads the market with 44% share, while Asia-Pacific is expected to record the fastest growth rate.

Johnson & Johnson's MedTech segment experienced mixed results in Q2 2026, with growth slowing due to weaker Cardiovascular sales and declining Abiomed procedures, though Shockwave showed strong double-digit growth. The company expects improvement in H2 2026 driven by Vision, Orthopedics, and Surgery segments, but faces ongoing headwinds from China's VBP program and competitive pressures.

Medtronic (MDT) closed at $87.97, up 1.84% in recent trading. The medical device company is projected to report EPS of $1.34 (down 1.47% YoY) and revenue of $9.47 billion (up 5.63% YoY). For the full year, analysts expect EPS of $5.98 and revenue of $38.96 billion. MDT carries a Zacks Rank #3 (Hold) with a Forward P/E of 14.45, trading at a discount to its industry average of 19.67.

Despite recent Fed rate hikes and rising Treasury yields, the article recommends two blue chip dividend stocks: AbbVie, a Dividend King with 53 consecutive years of dividend increases and strong growth prospects from new drugs, and Medtronic, which is on track to become a Dividend King with 49 consecutive years of dividend hikes and improving operational performance after recent restructuring.

The author recommends two high-yield dividend stocks for October: Medtronic (MDT), which has completed a business overhaul and is approaching Dividend King status with a 3.3% yield, and McCormick (MKC), a consumer staples company with 39 years of dividend increases and a 4.2% yield that is acquiring Unilever's food business to roughly double its sales.